Vicus Capital Sells 206 Shares of Johnson & Johnson (NYSE:JNJ)

Vicus Capital lowered its stake in Johnson & Johnson (NYSE:JNJ) by 2.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,870 shares of the company’s stock after selling 206 shares during the period. Vicus Capital’s holdings in Johnson & Johnson were worth $1,004,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Tennessee Valley Asset Management Partners lifted its stake in Johnson & Johnson by 3.1% during the fourth quarter. Tennessee Valley Asset Management Partners now owns 2,666 shares of the company’s stock worth $418,000 after purchasing an additional 80 shares during the last quarter. Private Client Services LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $279,000. Capital Analysts LLC boosted its stake in Johnson & Johnson by 1.5% in the fourth quarter. Capital Analysts LLC now owns 38,928 shares of the company’s stock valued at $6,102,000 after buying an additional 557 shares in the last quarter. Emfo LLC grew its position in Johnson & Johnson by 2.4% in the fourth quarter. Emfo LLC now owns 10,846 shares of the company’s stock valued at $1,700,000 after acquiring an additional 250 shares during the last quarter. Finally, LifePlan Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter worth about $228,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.1 %

Shares of NYSE JNJ traded down $0.24 during midday trading on Thursday, reaching $161.19. The stock had a trading volume of 857,703 shares, compared to its average volume of 7,268,479. The company’s 50 day moving average price is $153.21 and its 200 day moving average price is $153.15. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $167.78. The firm has a market cap of $387.93 billion, a price-to-earnings ratio of 10.04, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the previous year, the business earned $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. TD Securities decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, August 5th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Friday, August 16th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.